An interim analysis ( performed after 15 subjects completed the blinded phase ) revealed that 29 % ( 4 of 14 ) of subjects had a 10 % increase in LVESV after 6 months of sildenafil compared to 13 % ( 1 of 8 ) of subjects receiving placebo .